Engineered immune cells take on lupus in first human test
NCT ID NCT06150651
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new treatment for people with severe lupus that did not get better with standard medicines. The treatment uses a patient's own immune cells, modified in a lab to target and attack faulty immune cells causing the disease. Only 3 people took part, and the main goal was to check if the treatment is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE (SYSTEMIC LUPUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
King Chulalongkorn Memorial Hospital
Bangkok, Please Select, 10330, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New lupus drug CUG252 passes first safety check in small trial
- New lupus drug candidate ISH0613 enters first human safety trial
- Immune reset: CAR-T cells take on lupus and more
- Experimental CAR-T therapy takes aim at Hard-to-Treat lupus kidney disease
- New pill VENT-03 aims to calm lupus skin flares
- Experimental Donor-Cell therapy takes aim at tough autoimmune diseases